In Wednesday’s Wall Street session, Moderna Inc (NASDAQ:MRNA) shares traded at $25.40, down -0.59% from the previous session.
MRNA stock price is now -3.34% away from the 50-day moving average and -37.35% away from the 200-day moving average. The market capitalization of the company currently stands at $9.82B.
With the price target of $40, Citigroup recently initiated with Neutral rating for Moderna Inc (NASDAQ: MRNA). On February 18, 2025, Barclays Downgraded its previous ‘Overweight’ rating to ‘Equal Weight’ on the stock reducing its target price from $111 to quote $45, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Hussain Abbas, Director sold 312 shares of the company’s stock on Jun 11 ’25. The stock was sold for $8,736 at an average price of $28.00. Upon completion of the transaction, the Director now directly owns 580 shares in the company, valued at $14732.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 11 ’25, Director Hussain Abbas bought 312 shares of the business’s stock. A total of $8,736 was incurred on buying the stock at an average price of $28.00. A total of 11.44% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $23.15 and a high of $138.07. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.22, and a quick ratio of 4.14. The fifty day moving average price for MRNA is $26.2765 and a two-hundred day moving average price translates $40.54365 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for 2025-03-31. The net profit margin was -105.67% and return on equity was -29.34% for MRNA. The company reported revenue of $108.0 million for the quarter, compared to $167.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -35.33 percent. For the current quarter, analysts expect MRNA to generate $116.26M in revenue.
